Literature DB >> 8978256

Adverse events associated with mefloquine. Women may be more susceptible to adverse events.

M Phillips.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8978256      PMCID: PMC2353079          DOI: 10.1136/bmj.313.7071.1552c

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  2 in total

1.  Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers.

Authors:  P J Barrett; P D Emmins; P D Clarke; D J Bradley
Journal:  BMJ       Date:  1996-08-31

2.  User Acceptability Patterns for Mefloquine and Doxycycline Malaria Chemoprophylaxis.

Authors: 
Journal:  J Travel Med       Date:  1996-03-01       Impact factor: 8.490

  2 in total
  4 in total

1.  Investigation of the in vitro gender-specific partitioning of mefloquine in malarial infected red blood cells and plasma.

Authors:  Nongluk Seethorn; Walther H Wernsdorfer; Harald Noedl; Juntra Karbwang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

2.  Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine.

Authors:  M M van Riemsdijk; M C J M Sturkenboom; J M Ditters; J H M Tulen; R J Ligthelm; D Overbosch; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

Review 3.  Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.

Authors:  R Matthew Chico; Daniel Chandramohan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-07-07       Impact factor: 4.481

Review 4.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.